Immunologic Research

, Volume 41, Issue 1, pp 34–44 | Cite as

Graft-versus-host disease and immunosuppression



  1. 1.
    Gatti RA, Meuwissen HJ, Allen MJG, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366–9PubMedCrossRefGoogle Scholar
  2. 2.
    Reisner Y, Kapoor N, O’Reilly RJ, et al. Transplantation for severe combined immune deficiency with HLA-A,B,DR incompatible parental marrow cells fractionated by Soybean agglutinine and sheep red blood cells. Lancet 1981;2:327–31PubMedCrossRefGoogle Scholar
  3. 3.
    Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993;329:840–4PubMedCrossRefGoogle Scholar
  4. 4.
    Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369–76PubMedCrossRefGoogle Scholar
  5. 5.
    Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339–46PubMedCrossRefGoogle Scholar
  6. 6.
    Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004;22:2816–25PubMedCrossRefGoogle Scholar
  7. 7.
    Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogenic peripheral blood stem cell transplantation, acute graft versus host disease improves but not Chronic graft versus host disease. Blood 1999;94:1465–70PubMedGoogle Scholar
  8. 8.
    Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation. Blood 2001;98:2942–7CrossRefGoogle Scholar
  9. 9.
    Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903–11PubMedCrossRefGoogle Scholar
  10. 10.
    Billingham RE. The biology of graft-versus-host reactions. Lancet 1966;62:21–78Google Scholar
  11. 11.
    Billingham RE, Brent L. Quantitative studies on tissue transplantation immunity. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease. Philos Trans R Soc Lond 1959;242:439–77CrossRefGoogle Scholar
  12. 12.
    Ferrara JL. Pathogenesis of acute graft versus host disease; cytokine and cellular effectors. J Hematother Stem Cell Res 2000;9:299–306PubMedCrossRefGoogle Scholar
  13. 13.
    Hofmeister CC, Quinn A, Cooke KR, Stiff P, Nickoloff B, Ferrara JLM. Graft-versus-host disease of the skin: life and death on the epidermal edge. Biol Blood Marrow Transplant 2004;10:366–72PubMedCrossRefGoogle Scholar
  14. 14.
    Sullivan K, Agura E, Anasetti C. Chronic graft versus host with acute leukaemia. N Engl J Med 2004;351:2276–85CrossRefGoogle Scholar
  15. 15.
    Lee SJ, Vogelsang GB, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215–33PubMedCrossRefGoogle Scholar
  16. 16.
    Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: II Pathology Working Group Report. Biol Blood Marrow Transplant 2006;12:31–47PubMedCrossRefGoogle Scholar
  17. 17.
    Devetten MP, Vose JM. Graft-versus-host disease: how to translate new insights into new therapeutic strategies. Biol Blood Marrow Transplant 2004;12:815–25CrossRefGoogle Scholar
  18. 18.
    Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729–35PubMedCrossRefGoogle Scholar
  19. 19.
    Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005;11:814PubMedCrossRefGoogle Scholar
  20. 20.
    Gilman AL, Chan KW, Mogul M, Morris C, Goldman FD, Boyer M, Cirenza E, Mazumder A, Gehan E, Cahill R, Frankel S, Schultz K. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;3:327–34CrossRefGoogle Scholar
  21. 21.
    Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005;11:495–505PubMedCrossRefGoogle Scholar
  22. 22.
    Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:47–55PubMedCrossRefGoogle Scholar
  23. 23.
    Flowers MED. Traditional treatment of chronic graft versus host disease. Blood Marrow Transplant Rev 2002;12:5–8Google Scholar
  24. 24.
    Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988;72:555–61PubMedGoogle Scholar
  25. 25.
    Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004;104:3501–6PubMedCrossRefGoogle Scholar
  26. 26.
    Cutler C, Henry NL, Magee C, Li S, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:551–7PubMedCrossRefGoogle Scholar
  27. 27.
    Wolff D, Roessler V, Steiner B. Treatment of steroid resistant acute GVHD with Declizumab and Etanercept. Bone Marrow Transplant 2000;35:1003–10CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  1. 1.Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Clinical Hematopoietic Stem Cell Transplant ProgramChildrens Hospital Los AngelesLos AngelesUSA

Personalised recommendations